Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease
Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H
Journal of neurochemistry · 87 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Animal study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Government
- National Institutes of Health
- Government
- National Heart, Lung, and Blood Institute
- Government
- National Institute of Neurological Disorders and Stroke
- Government
- NHLBI NIH HHS
- Government
- NINDS NIH HHS
- Government
- NIH
- Grants
- National Heart, Lung, and Blood Institute (R01 HL085629); National Institute of Neurological Disorders and Stroke (R15 NS071459); National Heart, Lung, and Blood Institute (R01HL072166)
Based on 6 listed funder(s).
Publication
- Published
- 2014-01-03 · J Neurochem · vol. 129 · issue 3 · pp. 539–547
- Publisher
- Wiley
- Cited
- 133 citations · more than 95% of similar papers · 4.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 41 works
- Access
- Open access (repository copy)
- Research areas
- Endoplasmic Reticulum Stress and Disease · Ubiquitin and proteasome pathways · Autophagy in Disease and Therapy
- Keywords
- Sulforaphane, Huntingtin, Proteasome, Huntingtin Protein, Autophagy, Protein degradation, Huntington's disease, Chemistry, Cell biology, Ubiquitin, Proteasome inhibitor, Biology, Molecular biology, Pharmacology, Biochemistry, Mutant, Apoptosis, Medicine, Internal medicine, Disease
- MeSH
- hela cells, animals, mice, transgenic, humans, mice, huntington disease, disease models, animal, isothiocyanates, sulfoxides, proteasome endopeptidase complex, nerve tissue proteins, blotting, western, transfection, autophagy, male, hek293 cells, huntingtin protein
6 authors
From US
- Yanying LiuUniversity of South Dakota
- Casey L. HettingerUniversity of South Dakota
- Dong ZhangUniversity of South Dakota
- Khosrow RezvaniUniversity of South Dakota
- Xuejun WangUniversity of South Dakota
- Hongmin WangUniversity of South Dakota
Abstract
The ubiquitin proteasome system (UPS) is impaired in Huntington's disease, a devastating neurodegenerative disorder. Sulforaphane, a naturally occurring compound, has been shown to stimulate UPS activity in cell cultures. To test whether sulforaphane enhances UPS function in vivo, we treated UPS function reporter mice ubiquitously expressing the green fluorescence protein (GFP) fused to a constitutive degradation signal that promotes its rapid degradation in the conditions of a healthy UPS. The modified GFP is termed GFP UPS reporter (GFPu). We found that both GFPu and ubiquitinated protein levels were significantly reduced and the three peptidase activities of the proteasome were increased in the brain and peripheral tissues of the mice. Interestingly, sulforaphane treatment also enhanced autophagy activity in the brain and the liver. To further examine whether sulforaphane promotes mutant huntingtin (mHtt) degradation, we treated Huntington's disease cells with sulforaphane and found that sulforaphane not only enhanced mHtt degradation but also reduced mHtt cytotoxicity. Sulforaphane-mediated mHtt degradation was mainly through the UPS pathway as the presence of a proteasome inhibitor abolished this effect. Taken together, these data indicate that sulforaphane activates protein degradation machineries in both the brain and peripheral tissues and may be a therapeutic reagent for Huntington's disease and other intractable disorders. Accumulation of mutant huntingtin (mHtt) protein causes Huntington's disease (HD). Sulforaphane (SFN), a naturally occurring compound, increased proteasome and autophagy activities in vivo and enhanced mHtt turnover and cell survival in HD cell models. SFN-mediated mHtt degradation is mainly through the proteasome pathway. These data suggest that SFN can be a therapeutic reagent for treating HD and other intractable disorders.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.